Page 108 of 294: studies 1,071 to 1,080 of 2,939, newest first. Back to the psychedelic-assisted therapy overview
Orvosi hetilap September 13, 2026 Szabolcs Kéri
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...
The Journal of Physical Chemistry B September 12, 2026 Cong Zhang, Mingqi Li, Jing Ma et al.
Abstract Precise control over the thermodynamics and kinetics of receptor–ligand interactions is pivotal for manipulating physiological processes and developing targeted therapies. However, conventional pharmacological approaches often lack the spatiotemporal precision required for noninvasive in vivo modulation. Terahertz (THz) technology offers a promising alternative by using nonionizing...
Drugs Education Prevention and Policy September 11, 2026 Ewa Jankowska, Damian Swieczkowski
Background Despite growing interest in psychedelic research, the expectations and social contexts through which people interpret and integrate psychedelic experiences remain underexplored, particularly outside Anglophone settings. This study aimed to identify recurring thematic patterns in Polish-language Reddit discussions and to examine how global scientific narratives are interpreted within...
Neuropharmacology September 11, 2026 Laura Rullo, Loredana Maria Losapio, Hela Mrizak et al.
Alcohol use disorder (AUD) represents a major public health challenge, with current pharmacological and psychotherapeutic treatments showing limited efficacy. Recent clinical evidence suggests that MDMA-assisted psychotherapy may be effective for AUD, although concerns remain regarding its safety and potential for recreational use. This study investigated the effects of MDMA administration on...
September 11, 2026 Joseph M. Diehl, Christina Chwyl, Liliana Kennedy et al. preprint
The therapeutic relationship is considered central to psychedelic-assisted therapy, yet little empirical research has examined how it changes during 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) or relates to acute MDMA experiences and clinical outcomes, particularly for social anxiety disorder (SAD). This preregistered secondary analysis examined therapeutic alliance and...
ACS Pharmacology & Translational Science September 11, 2026 Damián Pobihuszka
Abstract Contemporary models of psychedelic action hold that clinical outcomes arise from an interaction between a pharmacologically induced brain state and the lived experience that unfolds within it. Research effort is distributed very unevenly across those two domains: pharmacological variables receive dose-finding trials, power calculations, and effect-size estimates, while the variables...
Journal of Psychedelic Studies September 10, 2026 Olivier Le Bon
Abstract Background The MDMA-assisted therapy landscape has been dominated by mostly holding-oriented, non-directive models. These approaches prioritize containment of the MDMA experience but leave largely unexploited the unique window of accessibility to unconscious material that MDMA creates. Objective This paper presents Active Deep Dive Therapy (ADDT), a theoretically grounded model for...
The International Journal of Neuropsychopharmacology September 9, 2026 Lisa Harada, K Yonezawa, K Kusudo et al.
Abstract Background Despite sequential treatments with conventional antidepressants, many patients with depression experience insufficient clinical improvement, referred to as treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic acting as a 5-HT2A receptor agonist, has attracted increasing attention as a novel treatment, with clinical trials demonstrating rapid and...
The International Journal of Neuropsychopharmacology September 9, 2026 Noemi Nicosia, Jessica Mingardi, G Terribile et al.
Abstract Background Chronic stress is a key risk factor for major depressive disorder (MDD), one of the leading causes of disability worldwide1. Despite available pharmacological therapies, treatment-resistant depression (TRD) remains a clinical challenge. Hallucinogens such as ketamine and serotonergic psychedelics including psilocybin and lysergic acid diethylamide (LSD)2 show rapid...
The International Journal of Neuropsychopharmacology September 9, 2026 J Ramaekers
Abstract Background Short-acting psychedelics such as 5-MeO-DMT and DMT may induce rapid relief of depressive symptoms after brief but intense psychedelic experiences. Aims & Objectives This presentation examines their clinical pharmacology and therapeutic potential in depression. Method Review of clinical data. Results Both compounds primarily target serotonergic receptors, notably 5-HT1A and...